DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Elliott - 1 BioMarin - 1 hemophilia - 1 Jean - 1 Jacques Bienaime - 1 Alexander Hardy - 1 Jefferies - 1 Bienaime - 1
Top related locs:
BioMarin San Rafael , California West Palm Beach , Florida New York
Top related orgs:
Investment Management - 1 BioMarin Pharmaceutical - 1 Biotechnology - 1 Alexion Pharma - 1 Svea - 1 Thomson - 1

Search resuls for: "Bienaime"


2 mentions found


☆ Exclusive: Activist investor Elliott targets drugmaker BioMarin -sources
  + stars: | 2023-11-07 | by ( Svea Herbst-Bayliss | ) www.reuters.com   time to read: +3 min
NEW YORK, Nov 7 (Reuters) - Activist investor Elliott Investment Management has built a stake in BioMarin Pharmaceutical (BMRN.O) and has been in discussions with the biotechnology company for months about its future, according to two people familiar with the matter. Elliott declined to comment, while a representative for BioMarin did not immediately respond to a request for comment. BioMarin shares rose 12% to $85.36 on the news in morning trading in New York on Tuesday. Prior to news of Elliott's engagement, BioMarin shares were down 24% year-to-date, significantly underperforming the iShares Biotechnology ETF (IBB.O), which is down 8.6%. Elliott also successfully pushed for drug makers Alexion Pharma (AZN.L) and Allergan (ABBV.N) to be sold.
Persons: Elliott, BioMarin, hemophilia, Jean, Jacques Bienaime, Alexander Hardy, Jefferies, Bienaime, Harvey, Richard Meier, Svea Herbst, Bayliss, Jamie Freed Organizations: Investment Management, BioMarin Pharmaceutical, Biotechnology, Alexion Pharma, Svea, Thomson Locations: BioMarin, San Rafael , California, West Palm Beach , Florida, New York
☆ A top Wall Street analyst names 6 major events that could send biotech stocks soaring between now and the end of 2022
  + stars: | 2022-11-14 | by ( Yeji Jesse Lee | ) www.businessinsider.com   time to read: +5 min
Cantor Fitzgerald analysts named six big events to mark on your calendar. While the majority of the expected events are set to come from smaller biotech companies, bigger companies — like Roche, Gilead, and Alnylam — have their own events coming through the pipeline. Here are the six major events from big biotech companies that could send stocks soaring:1. Cantor Fitzgerald analysts give Gilead's stock a neutral rating and they have an overweight rating on Arcus. Lenacapavir "could become a much bigger piece of the HIV growth narrative over the next few years," according to Cantor Fitzgerald analysts.
0 next >>
Total: 2